Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analysis of microbiome in gastrointestinal stromal tumors: Looking for different players in tumorigenesis and novel therapeutic options.
Ravegnini G, Fosso B, Ricci R, Gorini F, Turroni S, Serrano C, Pilco-Janeta DF, Zhang Q, Zanotti F, De Robertis M, Nannini M, Pantaleo MA, Hrelia P, Angelini S. Ravegnini G, et al. Among authors: pilco janeta df. Cancer Sci. 2022 Aug;113(8):2590-2599. doi: 10.1111/cas.15441. Epub 2022 Jun 21. Cancer Sci. 2022. PMID: 35633186 Free PMC article.
Emerging drugs for the treatment of gastrointestinal stromal tumors.
Pilco-Janeta DF, García-Valverde A, Gomez-Peregrina D, Serrano C. Pilco-Janeta DF, et al. Expert Opin Emerg Drugs. 2021 Mar;26(1):53-62. doi: 10.1080/14728214.2021.1896704. Epub 2021 Mar 10. Expert Opin Emerg Drugs. 2021. PMID: 33645383 Review.
Liquid Biopsy in Gastrointestinal Stromal Tumors: Ready for Prime Time?
Gómez-Peregrina D, García-Valverde A, Pilco-Janeta D, Serrano C. Gómez-Peregrina D, et al. Among authors: pilco janeta d. Curr Treat Options Oncol. 2021 Feb 27;22(4):32. doi: 10.1007/s11864-021-00832-5. Curr Treat Options Oncol. 2021. PMID: 33641024 Review.
E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor.
García-Valverde A, Rosell J, Sayols S, Gómez-Peregrina D, Pilco-Janeta DF, Olivares-Rivas I, de Álava E, Maurel J, Rubió-Casadevall J, Esteve A, Gut M, Valverde C, Barretina J, Carles J, Demetri GD, Fletcher JA, Arribas J, Serrano C. García-Valverde A, et al. Among authors: pilco janeta df. Oncogene. 2021 Dec;40(48):6614-6626. doi: 10.1038/s41388-021-02049-0. Epub 2021 Oct 7. Oncogene. 2021. PMID: 34621020
Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma.
Marino-Enriquez A, Novotny JP, Gulhan DC, Klooster I, Tran AV, Kasbo M, Lundberg MZ, Ou WB, Tao DL, Pilco-Janeta DF, Mao VY, Zenke FT, Leeper BA, Gokhale PC, Cowley GS, Baker LH, Ballman KV, Root DE, Albers J, Park PJ, George S, Fletcher JA. Marino-Enriquez A, et al. Among authors: pilco janeta df. Clin Cancer Res. 2023 Dec 15;29(24):5128-5139. doi: 10.1158/1078-0432.CCR-23-0998. Clin Cancer Res. 2023. PMID: 37773632
Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors.
He W, Xu L, Ding J, Song L, Yang W, Klooster I, Pilco-Janeta DF, Serrano C, Fang H, Jiang G, Wang X, Yu J, Ou WB. He W, et al. Among authors: pilco janeta df. Biochim Biophys Acta Mol Basis Dis. 2023 Jun;1869(5):166690. doi: 10.1016/j.bbadis.2023.166690. Epub 2023 Mar 13. Biochim Biophys Acta Mol Basis Dis. 2023. PMID: 36921738